Genital Herpes Treatment Drugs Market: Global Industry Trends, Market Size, Leading Players and Forecast 2018-2026

Thu Jan 10, 2019 - 10:30am UTC

The latest market report published by Credence Research, Inc. “Global Genital Herpes Treatment Drugs Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global genital herpes treatment drugs market is expected to expand at a CAGR of 4.9% from 2018 to 2026.

SANJOSE, United States – January 10, 2019

Market Insights
Genital herpes is the most common form of sexually transmitted disease in sexually active person. In the earlier stage of infection there are no visible symptoms reported but as the disease progresses genital lesions, cold sores, abnormal discharge and excruciating pain during micturition are clinically manifested. It is spread through oral, vaginal and anal contact. It is important to note that herpes infection is not cured only the symptoms are suppressed to promote relief in the ailing patients. Safe sex practice, early diagnosis and genital hygiene are the best preventive care to curb the spread of genital herpes infection. There is a changing trend in the treatment of genital herpes infection, wherein biologist are primarily focusing on developing vaccines to bolster immunity in ailing patients and address the problem of lesion recurrence.

Browse the full report Genital Herpes Treatment Drugs Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/genital-herpes-treatment-drugs-market

Acyclovir is presently dominating the drug class for the genital herpes treatment drugs market. The primary features responsible for the dominance of acyclovir are its excellent therapeutic efficacy, dose tolerance with negligible toxicity. It is currently the drug of first choice for the treatment of genital herpes with a prescribed dose of 200 mg five times daily for 10 days. Famciclovir has gained prominence on account of its higher oral bioavailability which is employed for the treatment of genital herpes patients suffering with lesion recurrence.

North America is currently reigning the geographical segment for genital herpes treatment drugs market. According to Center for Disease Control and Prevention (CDC), genital herpes is occurring 1in every 6 citizens in the United States. Rising prevalence of sexually transmitted disease and effective treatment guidelines drive the genital herpes treatment drugs market growth in North America. Affordable reimbursement scenario and domicile of major players such as AstraZeneca, Plc., GlaxoSmithkline, Plc. & Novartis AG. Propel the genital herpes treatment drugs market growth in the European region. Asia Pacific will register rapid growth during the forecast period from 2018 to 2026 owing to the rising prevalence of HSV-1 infected patients, increasing public health awareness and presence of huge generic drugs for the treatment of genital herpes infection.

Pharmaceutical companies providing medication for the treatment of genital herpes infection are AstraZeneca, Plc., Apotheca, Inc., Asahi Kasei Pharma Corporation, Carlsbad Technology, Inc., GlaxoSmithkline, Plc., Mylan N.V., Novartis AG., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Zydus Pharmaceuticals, Inc.

Key Market Movements:

Rising prevalence of sexually transmitted disease worldwide
Increasing public health awareness and affordable reimbursement scenario drive the genital herpes treatment drugs market
Excellent product pipeline catering therapeutics vaccines to bolster patient immunity such as GEN-003 and VCL-HB01

ToC:
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Genital Herpes Treatment Drugs Market Portraiture
2.2. Global Genital Herpes Treatment Drugs Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Genital Herpes Treatment Drugs Market, by Geography, 2017 (US$ Mn)

Chapter 3. Genital Herpes Treatment Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Genital Herpes Treatment Drugs Market, by Key Players, 2017

Chapter 4. Global Genital Herpes Treatment Drugs Market, by Drug Class
4.1. Overview
4.2. Acyclovir
4.3. Famciclovir
4.4. Valacyclovir
4.5. Pipeline Analysis
4.5.1. Phase III Drugs
4.5.1.1. GEN-003
4.5.1.2. VCL-HB01
4.5.2. Tabular Representation of Drug Pipeline in Phase II and I

Get Sample with more graphs and details for better understanding: https://www.credenceresearch.com/sample-request/59515

Browse the full report Genital Herpes Treatment Drugs Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/genital-herpes-treatment-drugs-market

………………..ToC Continued !

About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com/report/genital-herpes-treatment-drugs-market

This news is published on Reuters.

VCNN is your primary source for all venture capital news. We provide the latest breaking news and insider stories straight from the venture capital scene. Contact us at: hello@vcnewsnetwork.com